Cathy Eng, MD, FACP


Ongoing Clinical Trials in BRAF-Mutant CRC

Cathy Eng, MD, FACP, professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses ongoing clinical trials in the <em>BRAF</em>-mutant colorectal cancer patient population.

Cecile Pizot


A Study Examining Breast Cancer Mortality Rates Across 47 Countries

Cecile Pizot, a biostatistician in Epidemiology at the International Prevention Research Institute, discusses a study that examined breast cancer mortality rates across 47 countries.

Celeste Lebb


Using Immunotherapy for the Treatment of Melanoma

Celeste Lebb&eacute;, MD, from the H&ocirc;pital Saint Louis, in Paris, France, discusses the use of immunotherapy for the treatment of melanoma.

C.G. Evans, PhD


MiR-34a Link to PD-L1 May Mean New Immunotherapy in NSCLC

Two presentations at this year’s American Association for Cancer Research (AACR) annual meeting linked a specific microRNA (miRNA), miR-34a, to an active area in immunotherapy, programed cell death-1 (PD-1) protein and its ligand, PD-L1.

Chandra Diwakarla, BSc (Hons), MBBS


Hypogammaglobulinemia and Abiraterone Therapy for Metastatic Prostate Cancer

Description of&nbsp;3 cases whereby significant septic complications occurred in the setting of abiraterone use that were associated with&nbsp;hypogammaglobulinemia.

Chandra P. Belani, MD


Dr. Chandra P. Belani on the Importance of Immunotherapies in Treating Lung Cancer

Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, talks about how immunotherapies targeting PD-L1 and PD-1 are showing activity in lung cancer.

Charles A. (Trey) Leath, MD


Clinical Outcomes and Quality of Life in Ovarian Cancer

Charles A. (Trey) Leath III, MD, associate professor, gynecologic oncology, University of Alabama Birmingham Cancer Center, discusses a study that examined clinical outcomes and quality of life in ovarian cancer.

Charles Coombes, MD


Exploring Celecoxib for the Treatment of Breast Cancer

Charles Coombes, MD, professor of medical oncology, Imperial College London, discusses a study of celecoxib versus placebo in primary breast cancer patients.&nbsp;

Charles E. Geyer, Jr, MD


Geyer on Managing Toxicities of Olaparib in BRCA+/HER2- Breast Cancer

Charles Geyer, MD, advises his peers on how to manage the grade 3 or higher toxicities and any serious adverse events seen in the clinical trial setting with adjuvant olaparib.

Charles G. Drake, MD, PhD


Investigating Immunotherapy Treatment in Renal Cell Carcinoma

Charles G. Drake, MD, PhD, director of Genitourinary Oncology at New York Presbyterian/Columbia University Medical Center, discusses his thoughts on whether sunitinib would be more successful as a treatment for patients with renal cell carcinoma if used in the neoadjuvant setting.

Charles J. Ryan, MD


Use of ARN-509 in Prostate Cancer

Charles J. Ryan, MD, Professor of Clinical Medicine, Urology, Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF), discusses the use of ARN-509 and its efficacy in treating prostate cancer.

Charles L. Shapiro, MD


The Results of the IBIS II Trial

Charles L. Shapiro, MD, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.

Charles M. Perou, PhD


Dr. Charles M. Perou on the Evolution of Precision Medicine in Breast Cancer

&#8203;Charles M. Perou, PhD, professor of Genetics, Pathology & Laboratory Medicine, Lineberger Comprehensive Cancer Center, UNC School of Medicine, discusses precision medicine in breast cancer and currently known biomarkers.

Charles M. Rudin, MD, PhD


Stimulating the Immune System With Coxsackievirus in Advanced Cancer Patients

Charles M. Rudin, MD, PhD, chief, thoracic oncology, Memorial Sloan Kettering Cancer, discusses a study of intravenously delivered coxsackievirus A21 with pembrolizumab to treat patients with advanced cancers.

Charles Perou, PhD


Dr. Charles Perou on Molecular Differences in Lobular Breast Cancer

Perou says this research also found three expression subtypes within lobular breast cancer, one of which showed a proliferative phenotype and portended a slightly worse prognosis.

Charles S. Fuchs, MD, MPH


The Future Treatment Landscape of Gastric Cancer

Charles S. Fuchs, MD, MPH, professor of Medicine, director, Yale Cancer Center, and physician-in-chief, Smilow Cancer Hospital, discusses what he envisions for the future treatment landscape of gastric cancer.

Charu Aggarwal, MD, MPH


Closing Thoughts on Recent Data in Non–Small Cell Lung Cancer

Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key NSCLC data updates discussed following the 2023 ASCO Annual Meeting.

Chase Doyle


Use of Anthracyclines Plus Taxanes Found to be Beneficial in Early, HER2-Negative Breast Cancer

Treatment with anthracyclines was proven to be beneficial for patients with high-risk, HER2-negative, early-stage breast cancer.

Chau Dang, MD


Case 2: Safety Considerations in the Use of T-DXd for HER2+ mBC

A key opinion leader in oncology shares expert perspectives on safety considerations when treating patients with T-DXd in the second-line setting for HER2+ mBC.

Chelsea LoCascio


CDK4&6 Inhibitors Revolutionize Hormone-Positive Breast Cancer Care

Denise A. Yardley, MD,&nbsp;discusses the promise of CDK4&amp;6 inhibitors in estrogen receptor (ER)-positive breast cancer, as well as the potential with immunotherapy agents.&nbsp;

Cheryl Alkon


Effective Options Arise for Patients With ALK-Positive NSCLC

New treatments that are currently in development have begun to show promise for patients diagnosed with ALK-positive non-small-cell lung cancer (ALK+ NSCLC), a subset of patients who have historically faced poor outcomes.

Cheryl Zigrand


Searching for Positives in Triple-Negative Breast Cancer

Treatments for triple-negative breast cancer (TNBC) have made significantly less progress in comparison with other subtypes.

Chiara Cremolini, MD


FOLFOXIRI plus Bevacizumab for Metastatic Colorectal Cancer

Chiara Cremolini, MD, discusses the phase III TRIBE trial, which compared FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as for patients with metastatic colorectal cancer.

Christian Jackisch, MD, PhD


Achieving a Higher pCR Rate With Nab-Paclitaxel in Breast Cancer

Christian Jackisch, MD, PhD, Professor of Obstetrics and Gynecology&nbsp;and&nbsp;Head of the Department&nbsp;of Obsterics and Gynaecology, Sana Klinikum Offenbach in Germany, discusses results of the GeparSepto study, as well as how a higher pathologic complete response (pCR) rate is achieved with nab-paclitaxel (Abraxane) in breast cancer.

Christiane K. Kuhl, MD


Dr. Christiane Kuhl Discusses Breast MRI Screening of Women at Average Risk of Breast Cancer

Christiane K. Kuhl, MD, Department of Diagnostic and Interventional Radiology, RWTH University of Aachen, discusses an observational cohort study looking at breast MRI screening of women at average risk of breast cancer.

Christiane Kuhl, MD


Dr. Christiane Kuhl on the Overdiagnosis of Breast Cancer

Christiane Kuhl, MD, Professor of Radiology and Vice Chairman of the Radiological department, Director of the Division of Oncologic Imaging and Interventional Therapy, Bonn University, talks about the over diagnosis of breast cancer through mammography screenings.